Argos Therapeutics Breaks Ground on State-of-the-Art Biomanufacturing Facility in Research Triangle Park Area
Argos Therapeutics broke ground on a new 100,000 sq ft biomanufacturing facility in the Research Triangle Park area in Durham, North Carolina. The facility may lead to more than 230 new jobs and will include advanced equipment for automated manufacturing of Arcelis-based products. Special guests at the groundbreaking ceremony (21 October 2014) included Bill Bell, Mayor of Durham, Bill Brian, Chairman Elect, Greater Durham Chamber of Commerce, and Michael Page, Chairman, Durham County Commission.
"We founded Argos in the Research Triangle Park area and I am glad that our new state-of-the-art manufacturing facility will be right here in this rapidly growing global center for biomedical research," said Jeff Abbey, President and CEO of Argos. "Durham is the ideal location for us to attract the experienced talent we need to expand our operations as we continue the development of our Arcelis-based products."
Argos received approximately $9.5 million in incentives from the State of North Carolina, Durham County, the City of Durham, and the North Carolina Biotechnology Center for the development and implementation of the facility, which will support automated production of the company's Arcelis-based personalised immunotherapy product candidates for the treatment of cancer and infectious diseases. AGS-003, the company's lead oncology product candidate, is currently being evaluated in the pivotal ADAPT phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC).
The incentive package from the North Carolina Department of Commerce to support the project totals $7.1 million, including a $4.5 million Job Development Investment Grant, $600,000 in education and on-the-job training assistance, a $1.8 million sales tax exemption on qualifying equipment, and a $200,000 Economic Development Award from the North Carolina Biotechnology Center. In addition to NC Commerce, the City of Durham and Durham County awarded an incentives package totaling $2.35 million including a cash grant of $1.85 million and $500,000 in on-the-job training assistance.
"Argos is a very important project to Durham," said William "Bill" Bell, Mayor, City of Durham. "I extend my congratulations not only for what this firm has done, but equally important for what Argos will do in the future for our community, its workforce and particularly for Argos developing new products that will help patients."
Related News
-
News Moderna to buy OriCiro Genomics in USD $85 million deal
Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio. -
News New year, new prices: at least 350 drugs in USA to see price increases in January
Drugmakers such as Pfizer, GSK, BMS, AstraZeneca, and Sanofi are planning to raise prices for at least 350 unique drugs in the United States in early January. -
Sponsored Content 2023 Pharma Trend Outlook: Innovation, Resilience, and Pharma 4.0
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain. -
News Strategic partnership between AstraZeneca and G42 Healthcare to increase pharmaceutical manufacturing in Abu Dhabi
A comprehensive, long-term partnership agreement between AstraZeneca and G42 Healthcare is set to enhance local drug manufacturing in Abu Dhabi, UAE, and bolster pharmaceutical manufacturing innovation within the country. -
News CordenPharma joins sustainability initiative to achieve Net Zero
The CDMO has joined the environmental initiative looking to align private sector companies with those aims upheld by the Paris Agreement to reduce global warming. -
News AstraZeneca acquires Neogene in shift into cell-based cancer therapies
AstraZeneca has recently announced that it will be acquiring the biotechnology company Neogene Therapeutics as part of it’s expansion into cell-based cancer treatments.
-
News A mRNA universal flu vaccine is in early stages of development
Researchers from the University of Pennsylvania have developed a universal flu vaccine using nanoparticle encapsulated mRNA. -
News Biovac partnership to increase African vaccine manufacturing capabilities
South African biopharma company Biovac signs a partnership deal with the International Vaccine Institute to develop and manufacture an oral cholera vaccine for both the African and global market.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance